EP
GRCE

Eversept Partners’s Grace Therapeutics GRCE Stock Holding History

Eversept Partners’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75M Buy
772,900
+16,300
+2% +$45.1K 0.09% 95
2026
Q1 		$3.5M Buy
+756,600
New +$2.97M 0.18% 69

Other funds holding GRCE

Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Eversept Partners's GRCE Position: Q2 2026 in Review

Eversept Partners increased its Grace Therapeutics (GRCE) stake by 2.2% in Q2 2026, buying an estimated $45.1K and bringing the position to 772,900 shares worth $1.75M. The position accounts for 0.09% of the portfolio, ranked #95.

Eversept Partners first reported a position in GRCE in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.5M in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

  • Eversept Partners held 772,900 shares of Grace Therapeutics worth $1.75M as of Q2 2026.
  • Eversept Partners bought 16,300 Grace Therapeutics shares in Q2 2026, an estimated $45.1K.
  • Grace Therapeutics made up 0.09% of Eversept Partners's portfolio in Q2 2026, its #95 holding.
  • Eversept Partners first reported a position in Grace Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Eversept Partners's Grace Therapeutics position peaked at $3.5M in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.